Overview on the hot topics of ECTRIMS 2023 and detailed look into the vision of curing MS, MS and EBV and MS in the elderly.

you can read the full text with some more details on the statistics of the trials on my blog: https://ms-perspektive.com/030-ectrims-2023-day-1

MS Milan 2023 was the 9th joint meeting of the European ECTRIMS and American ACTRIMS congress. Over 8,600 participants from 108 countries joined and had the chance to listen to 240 faculty members and diggest the input from 1,915 abstracts.

Ten hot topics where defined:

1. MS and EBV
2. Treatment screening and monitoring
3. MS in the elderly
4. Which biomarker and when?
5. Future therapeutic strategies
6. PIRA and silent progression
7. New technologies for MS patients
8. Prodromic MS
9. HSCT in MS
10. Biomarkers of damage and recovery

I will try to pick some interesting outcomes on most of them during my summary of the three days starting with the the ECTRIMS lecture by Dr. Stephen L. Hauser and continuing with MS and EBV, and MS in the elderly.

Table of Contents

• Opening Session and ECTRIMS lecture: Multiple Sclerosis: Path to a Cure by Stephen L. Hauser, MD
• Hot Topic 1: MS and EBV – implications for management and treatment
• Clinical progression and decision making
• Hot Topic 3: MS in the elderly

---

The speech by Stephen L. Hauser was very inspiring. EBV remains an interesting therapeutic goal, but it seems to be difficult and a long way to come up with trial scenarios that would have an impact on the MS burden. MS in the elderly is a burning topic and will become more crucial year to year as the MS population is aging. I'm glad scientists are starting to look into this topic more and more. And on the aspect of personal medicine it would be great to find out how to best treat each individual, when to stop DMTs and to find effective ways to tackle progression in MS.

See you soon and try to make the best out of your life, Nele

For more information and positive thoughts, subscribe to my newsletter for free.

Click here for an overview of all podcast episodes published so far.